๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Five Years of Treatment with Risedronate and its Effects on Bone Safety in Women with Postmenopausal Osteoporosis

โœ Scribed by L.-G. Ste-Marie; E. Sod; T. Johnson; A. Chines

Publisher
Springer
Year
2004
Tongue
English
Weight
135 KB
Volume
75
Category
Article
ISSN
1432-0827

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Seven Years of Treatment with Risedronat
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
โœ D. D. Mellstrรถm; O. H. Sรถrensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› Springer ๐ŸŒ English โš– 186 KB

The effects of 7 years of risedronate treatment were evaluated in a second 2-year extension of a 3-year vertebral fracture study in women with osteoporosis. For the first 5 years of the study, women received risedronate 5 mg/day or placebo according to the original randomization, with maintenance of

Effects of bazedoxifene on bone mineral
Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis
โœ Akira Itabashi; Kousei Yoh; Arkadi A Chines; Takami Miki; Masahiko Takada; Hiros ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American Society for Bone and Mineral Research ๐ŸŒ English โš– 244 KB ๐Ÿ‘ 2 views

## Abstract This randomized, doubleโ€blind, placeboโ€controlled, doseโ€response late phase 2 study evaluated the efficacy and safety of bazedoxifene in postmenopausal Japanese women 85 years of age or younger with osteoporosis. Eligible subjects received daily treatment with oral doses of bazedoxifene